logo


Zacks Analyst Blog Highlights: Coca-Cola Hellenic Bottling Co., Regeneron Pharmaceuticals, Inc., Denbury Resources Inc., Kinross Gold Corp. And Trimeris, Inc. - Nov 8 2008 12:31PM
Friday, November 07, 2008 12:32 PM


(Source: BUSINESS WIRE)trackingZacks.com

Mark Vickery

Web Content Editor

312-265-9380

Visit: www.zacks.com

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Coca-Cola Hellenic Bottling Co. (NYSE: CCH), Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), Denbury Resources Inc. (NYSE: DNR), Kinross Gold Corp. (NYSE: KGC) and Trimeris, Inc. (Nasdaq: TRMS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Thursday's Analyst Blog:

Coca-Cola Hellenic a Buy

Coca-Cola Hellenic Bottling Company (NYSE: CCH) enjoys an attractive geographic mix with 66% of revenues being derived from developing or emerging markets. In addition, the company's product mix is less dependent on CSDs (carbonated soft drinks) than other bottlers.

Since the company conducts business and reports financial results in Euros, much of the stock's performance is inversely correlated with US dollar's exchange rate with the Euro. However, as management has a sound business strategy and proven execution skills, the recent earnings decline is providing a valuation-based buying opportunity.

Regeneron a Growth Biotech Play

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) is a biopharmaceutical company engaged in the development and marketing of therapeutic medicines for the treatment of serious medical conditions. Its lead candidates are VEGF-Trap for the treatment of cancers, eye diseases, and IL-1 Trap for CAPS and gout.

The company recently received the FDA approval of Arcalyst for CAPS [Cryopyrin-Associated Periodic Syndromes: auto-inflammatory diseases which share a number of common symptoms]. It also has a number of pre-clinical drug candidates for other disorders.

Denbury Rescs a Lower-Target Buy

Plano, Texas-based Denbury Resources Inc. (NYSE: DNR) is a growing exploration and production (E&P) company engaged in the acquisition, development, operation, and exploration of oil and natural gas properties in the U.S. Gulf Coast region. It is the largest oil and gas producer in Mississippi, and also has properties in Louisiana, Alabama and the Barnett Shale area of Texas.

Denbury's third-quarter results were significantly above the year- earlier level due to production gains and higher realized prices for crude and natural gas. Production rose 12%, after adjusting for the sale of Louisiana natural-gas properties, while average realized crude oil and natural gas prices increased 53% and 10% year-over- year, respectively.



(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

  
Related Press Releases
Advertisement
Popular Articles
Advertisement
Partner Center
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia